Rocio Martin Hoyos
CIK: 0002107515
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RNA
Atrium Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Hoyos Rocio Martin
Hoyos Rocio Martin (SEC CIK 0002107515) files insider reports with the SEC as Chief Strategy Officer of Atrium Therapeutics, Inc. (RNA).
Signal8 holds 3 ownership filings by Hoyos Rocio Martin (1 Form 3, 2 Form 4), filed between Feb 26, 2026 and Sep 22, 2026. Those filings report 2 transactions, from Apr 20, 2026 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hoyos Rocio Martin's filings is in SAN DIEGO, CA.
Recent filings by Hoyos Rocio Martin
Other insiders filing for Atrium Therapeutics, Inc. (RNA)
- Younis Husam, Chief Scientific Officer
- Hughes Steven George, Chief Medical Officer
- Flanagan W. Michael, Director
- Boyce Sarah, Director
- Kenney Stephanie
- Gallagher Kathleen P.